carbidopa/levodopa / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 61 Diseases   24 Trials   24 Trials   800 News 


«12345678910111213...1314»
  • ||||||||||  Comtan (entacapone) / Novartis, Orion Corp, Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
    Journal:  Patients' Preferences for Adjunctive Parkinson's Disease Treatments: A Discrete-Choice Experiment. (Pubmed Central) -  Sep 19, 2023   
    The attributes and levels selected for this study were intended to reflect the characteristics of opicapone and entacapone; attributes associated with other adjunctive therapies were not evaluated. Patients with PD expressed interest in adjunctive treatment to increase ON time and would accept reduced ON time to avoid adverse effects.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    An Interesting Case of COVID-19 related Parkinsonism () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1885;    
    In a predisposed individual, COVID-19 illness can result in parkinsonism. To ascertain if the impact on dopaminergic activity is short-term or long-lasting, more research is required.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Stability and predictability of motor symptom control in patients with advanced Parkinson () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1440;    
    P3
    Patients on LDP/CDP were more likely to wake up in good ON and experienced fewer motor fluctuations within 1 wk, with improvements up to 52 wk. Stability of motor symptoms permits patients greater predictability of motor responses, which may improve quality of life throughout the morning, day and night.
  • ||||||||||  Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
    Improvements in Parkinson () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1413;    
    Most presumed infusion site infections were managed with empiric oral antibiotics and did not lead to discontinuation of therapy. Objective: To describe motor complications as measured by the Movement Disorder Society-Unified Parkinson
  • ||||||||||  Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
    Characterisation of OFF-Time in Levodopa-Treated Parkinson () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1388;    
    Long-term CSCI of LDP/CDP was generally safe and well tolerated and effected sustained improvements in motor fluctuations and morning akinesia that were consistent with the parent study. Objective: This analysis aims to study the evolution of OFF and ON patterns during a 12-hour daily period in patients with Parkinson
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Improvement of nocturia symptoms and associated quality of life in patients with Parkinson () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1376;    
    P3
    Objective: This analysis aims to study the evolution of OFF and ON patterns during a 12-hour daily period in patients with Parkinson Use of LDP/CDP CSCI in patients with PD leads to reductions in patient-reported symptoms of nocturia that may be correlated with improvement in QoL.
  • ||||||||||  Deep brain stimulation for the management of movement disorders in Rett syndrome () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1141;    
    Treatment of tremor included benzodiazepines, carbidopa-levodopa, propranolol, and primidone; each was discontinued either due to insufficient benefit or intolerable side effects...Treatment included carbidopa-levodopa, clonazepam, botulinum neurotoxin injections, and intrathecal baclofen pump all with insufficient benefit.; The first patient underwent bilateral VIM/PSA-DBS was implantation and had significant improvement in the intermittent tremor exacerbations per caregiver report... Although this is a small, observational series and no objective measures were used, both patients
  • ||||||||||  clonazepam / Generic mfg., primidone / Generic mfg., carbidopa/levodopa / Generic mfg.
    Jerky dystonic hand revisited: post-stroke thalamic tremor (C1 M1, Ground floor) -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1125;    
    Post thalamic stroke MDs have a mixed phenomenology. On the basis of the clinical phenomenology at presentation, a fairly accurate anatomical and radiological correlation can be made.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Drug-induced Parkinsonism and nonmotor symptoms: a case of gustatory rhinorrhea () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_980;    
    Gustatory rhinorrhoea, although a rare manifestation, has already been reported in association with PD. Up to this time and in the light of the authors knowledge, this is the first case-report of gustatory rhinorrhoea related to DIP.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Can very early levodopa prevent self-injury in Lesch-Nyhan Disease? (Auditorium 12 (First floor)) -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_952;    
    Up to this time and in the light of the authors knowledge, this is the first case-report of gustatory rhinorrhoea related to DIP. Based on the hypothesis that very early levodopa treatment may prevent the development of the full phenotype, we attempted to restore dopamine levels in 3 infants with LND.; We treated 3 infants with LND off-label with levodopa/carbidopa (ratio 4:1), starting at 11
  • ||||||||||  amantadine / Generic mfg.
    A Retrospective Review of Amantadine in Progressive Supranuclear Palsy () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_706;    
    Symptomatic treatment for PSP typically begins with trial of carbidopa-levodopa, but in most cases levodopa is poorly effective and provides only modest benefit. Although a small percentage of PSP patients tolerated and reported subjective benefit from amantadine, objectively, amantadine did not improve PSPRS scores and may worsen symptoms or cause adverse effects.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Case of neuroferritinopathy with isolated dystonic leg cramps and normal neuroimaging () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_373;    
    Our case exemplifies a rare phenomenon of normal neuroimaging in a genetically proven case of NF. Also, to the best of our knowledge, isolated dystonic leg cramps have not been described as the initial presentation in a case of NF.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Voice- tremor in a patient with positive VPS 16 nonsense mutation: Expanding the phenotype () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_371;    
    Although he did not have a response to levodopa-carbidopa combination of 125 mg thrice a day, he had a significant response to trihexyphenidyl in the form of reduced neck posturing and tremors in neck and voice. Voice tremors can be the initial presentation of VPS-16 positive early adulthood onset dystonia.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial completion date, Trial primary completion date:  Sustained Release Oral Formulation for Treatment of Parkinson's Disease (clinicaltrials.gov) -  Aug 23, 2023   
    P1,  N=6, Not yet recruiting, 
    An early trial of levodopa can improve the quality of life of patients with SPG11 mutations Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2024
  • ||||||||||  neramexane (KRP-209) / AbbVie
    Journal:  Literature-Based Discovery Predicts Antihistamines Are a Promising Repurposed Adjuvant Therapy for Parkinson's Disease. (Pubmed Central) -  Aug 16, 2023   
    The relationship patterns among the identified adjuvant candidates suggest that the likely therapeutic mechanism(s) of action of antihistamines for combatting the multi-factorial PD pathology include counteracting oxidative stress, amending the balance of neurotransmitters, and decreasing the proliferation of inflammatory mediators. Finally, cross-domain text mining interestingly predicted a strong relationship between PD and liver disease.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial completion date, Trial primary completion date:  ESTREL: Enhancement of Stroke Rehabilitation With Levodopa (clinicaltrials.gov) -  Aug 16, 2023   
    P3,  N=610, Recruiting, 
    Finally, cross-domain text mining interestingly predicted a strong relationship between PD and liver disease. Trial completion date: Dec 2022 --> Dec 2028 | Trial primary completion date: Dec 2022 --> Aug 2024
  • ||||||||||  pentoxifylline / Generic mfg.
    New P2 trial:  Pentoxifylline and Parkinsonism (clinicaltrials.gov) -  Jul 27, 2023   
    P2,  N=50, Not yet recruiting, 
  • ||||||||||  cabergoline / Generic mfg., carbidopa/levodopa / Generic mfg.
    Late-Onset Symptomatic Hyperprolactinemia in 6-Pyruvoyl-Tetrahydropterin Synthase Deficiency (Exhibitions Hall (ICC)) -  Jul 11, 2023 - Abstract #SSIEM2023SSIEM_494;    
    Trial completion date: Dec 2022 --> Dec 2028 | Trial primary completion date: Dec 2022 --> Aug 2024 Thirteen patients (7 females and 6 males) with PTPS deficiency diagnosed by newborn screening and currently aged 23.5
  • ||||||||||  Trial completion date, Trial primary completion date:  Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure (clinicaltrials.gov) -  Jun 18, 2023   
    P2,  N=80, Recruiting, 
    These data suggest that the positive effects of L-theanine on motor coordination may be Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Mar 2023 --> Aug 2023
  • ||||||||||  metformin / Generic mfg.
    Enrollment open, Trial initiation date:  Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease (clinicaltrials.gov) -  Jun 7, 2023   
    P2,  N=60, Recruiting, 
    The described method was successfully applied to a 45-year-old male patient to compare the pharmacokinetic behavior of an L-DOPA-based medical treatment involving commercially available Mucuna pruriens extracts and an LDME/carbidopa (100/25 mg) formulation. Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Jan 2023